| INTRODUC TI ON
Melanoma is a highly mutated and aggressive type of cancer originated from the malignant transformation of melanocytes.
Most commonly, melanoma arises from skin melanocytes (acral and non-acral cutaneous melanoma), but it can occasionally originate from melanocytes present in other parts of the body, such as meninges, cochlea, the mucosae (mucosal melanoma), and the uvea of the eye (uveal melanoma). Acral melanoma, a relatively rare subtype, arises from non-hair-bearing skin locations, such as the palms of the hands, the soles of the feet, or the nail bed (subungual areas). The non-acral cutaneous melanoma comprises three major subtypes, superficial spreading melanoma, which is the most prevalent form and usually occurs in the trunk; nodular melanoma, the second most prevalent and highly invasive form; and lentigo maligna melanoma, associated with long-term sun-exposed skin (Scolyer, Long, & Thompson, 2011) . Most non-acral cutaneous melanoma are considered sporadic in nature, and recent genomewide mutational studies show that they are associated with the ultraviolet light (UV) signature, implicating sunlight exposure as a causal factor .
Whole exome sequencing (The Cancer Genome Atlas Network, 2015) led to the genomic classification of cutaneous melanoma into four subclasses according to cancer driver mutations: mutant BRAF (~52%), mutant RAS (~30%); mutant NF-1 (~14%); and triple wild-type, those with no mutations in any of the three genes.
All three genes encode components of the classical mitogen-activated protein kinase (MAPK/ERK) cascade, encompassing RAS-RAF-MEK-ERK, the major pathway that transmits extracellular mitogen signals downstream from activated tyrosine kinase receptors to elicit diverse cellular responses, such as growth, motility, and survival. While BRAF and RAS are oncogenes, NF-1 is a tumor suppressor gene that codes for a RAS-GAP, responsible for the inactivation of RAS. Therefore, mutations in BRAF, RAS, and NF-1 genes seem to lead to equivalent constitutive activation of the MAPK/ERK pathway, and for this reason, or perhaps due to deleterious effects of coexisting mutations, they almost always are found to be mutually exclusive. Activating mutations of genes implicated in the PI3K pathway are also highly frequent in melanoma, and activation of PI3K-AKT-mTOR signaling pathway cooperates with the MAPK pathway to set the scenario of sustained growth and death resistance in melanoma. Driver mutations coexist with activating mutations in the TERT gene promoter or in other genes implicated in telomere maintenance required for replicative immortality .
Inhibitors of the mutated BRAF kinase (vemurafenib and dabrafenib) , as well as a combination of BRAF inhibitor with MEK inhibitor (trametinib) and, more recently, immunotherapy are in clinical use to treat melanoma with unprecedented success (for review, Luke, Flaherty, Ribas, & Long, 2017; Melino et al., 2016) .
However, therapeutic resistance and side effects remain major challenge, and not all patients can benefit from these treatments. (Bartonicek et al., 2017; Gong, Liu, Zhang, Miao, & Guo, 2015) .
There are bona fide examples of lncRNA linked to one or multiple hallmarks of cancer in a variety of cancers, including melanoma, in which many emerge as regulators of the MAPK and PI3K pathways (for review, Huang et al., 2018; Leucci, Coe, Marine, & Vance, 2016; Schmitt & Chang, 2016; Tasharrofi & Ghafouri-Fard, 2018 ).
RMEL3 lncRNA was first identified in a previous study of our group as a melanoma-restricted gene in a data mining analysis of ESTs exclusively originated from melanoma sources (Sousa et al., 2010) . RMEL3 is not expressed in melanocytes, but it is widely expressed in nevi, primary, and metastatic melanoma. It was subsequently linked to BRAFV600E mutation, based on expression analysis in a large set of melanoma cell lines and the TCGA melanoma dataset (The Cancer Genome Atlas Network, 2015) then available (Goedert et al., 2016) . The later work also demonstrates that RMEL3 knockdown leads to alterations in the expression levels of mRNA and proteins of many components of the MAPK and PI3K pathways. This result was consistent with the observed loss of clonogenic ability and increased arrest in the G1 phase of the cell cycle in a set of RMEL3-knockdown cells, with 
| MATERIAL S AND ME THODS

| Cell culture
Human melanoma cell lines WM278 and WM1617 were kindly provided by Dr. Meenhard Herlyn (Wistar Institute, Philadelphia, PA), and we did an HLA typing for the cells that we carry in our laboratory and confirmed that they constitute a pair of cell lines originated from the same patient, as originally described. The cells were maintained in TU medium with 2% (v/v) fetal bovine serum (FBS) . All the following cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS, 50 U/mL penicillin, and 50 mg/ml streptomycin. The melanoma cell lines (WM1366, Skmel-147, Skmel-103, Skmel-19, Skmel-28, and UACC-62) Halaban (Yale University). Primary melanocytes were cultured in TIVA medium (F-10 with 10% FBS, 50 ng/ml TPA, 225 μM IBMX, 1 μM Na 3 VO 4 , and 1 mM dbcAMP; all from Sigma-Aldrich, St. Louis, MO). All cultures were kept at 37°C under a 5% CO 2 humidified atmosphere. 
| Human melanoma tissue samples
| RNA isolation
Total RNA was extracted using TRIzol® (Invitrogen, Carlsbad, CA).
It was then treated with DNase I (DNA-free kit, Ambion, Austin, TX) and converted into cDNA using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA). All protocols were performed according to manufacturer's instructions. Cycle threshold (Ct) was converted to relative expression according to the 2 -ΔΔCT method, using TBP (TATA-box binding protein) as endogenous control. washed with PBS, and resuspended in PBS containing 10 μg/mL of propidium iodide. These cells were counted in a flow cytometer (Guava® easyCyte™ 8HT Flow Cytometry System-Millipore).
| Expression analysis by RT-qPCR
| Pharmacological treatment and viability assay
| Western blot analysis
Cells were homogenized in a sample buffer containing 0.1% SDS and subjected to SDS-PAGE. Proteins were blotted onto a nitrocellulose membrane (Hybon-ECL; Amersham Biosciences, Arlington, IL). Membranes were incubated with diluted primary antibody in TBS-Tween-20 0.05% + BSA 2% overnight at 4°C. Subsequently, the membrane was incubated with corresponding secondary antibody coupled with horseradish peroxidase (Nichirei Co, Tokyo, Japan). Peroxidase reaction products were visualized using the ECL Plus detection system (Amersham Biosciences). Antibodies were used according to the manufacturer-recommended dilution.
Primary antibodies anti-phosphorylated ERK1/2 and anti-total ERK1/2 were purchased from Cell Signaling Technology, Beverly, MA, USA.
| RMEL3 cDNA cloning, transduction, and expression
Total RNA from WM278 melanoma cells was extracted using TRIzol Lentiviral particles collected from HEK293T culture media were used to transduce VM10 melanoma cell line. Infected cells were selected with 1 μg/mL puromycin for 3 days.
| Proliferation assay
Cells were seeded in 96-well culture dishes at a density of 5.000 cells/well, for Skmel103 and VM10, and 500 cells/well for NIH3T3.
The melanoma cell lines Skmel103 and VM10 were cultured in FBSfree DMEM and DMEM Complete Medium, respectively, whereas NIH3T3 cells were cultured in 0.5% FBS DMEM. Culture medium was removed, and cells were fixed with 70% ethanol, at room temperature for 10 min. Ethanol was removed, and crystal violet (0.5% in water) was added and incubated for 30 min at room temperature. The fixed cells were washed five times with water, followed by addition of 10% acetic acid, and incubated for 30 min at room temperature. Absorbance at 540 nm was measured using an ELISA microplate reader.
| Clonogenic assay
Cells overexpressing RMEL3 and paired controls were plated in 60-mm tissue culture dishes (600 cells/dish) in DMEM supplemented with 10% FBS. Cells were incubated at 37°C, in 5% CO 2 humidified atmosphere, for 9 days (NIH3T3) and 14 days (Skmel103). After the specified period, cells were fixed with 4% paraformaldehyde and stained with 0.5% crystal violet for visualization of colonies. The plates were photographed, and the colonies were quantified to determine the clonogenic ability.
| Apoptosis assay
NIH3T3 cells were seeded in 24-well plates at 2 x 10 4 cells/well in DMEM supplemented with 10% FBS. After 24 hr, the medium was changed to FBS-free medium for 48 hr and then to 0.5% FBS medium for additional 48 hr. For detection of apoptotic and unviable cells, we used the annexin-V, Alexa Fluor® 488 conjugate (Life Technologies), and Propidium Iodide (Life Technologies). This protocol was performed according to manufacturer's instructions.
| Tumor xenograft assay
SKMEL103 melanoma cells stably transduced with pLVX-TP (control)
or pLVX-RMEL3 were cultured in complete media supplemented with 1 μg/ml doxycycline to confluence. Ten 8-week-old male nude mice were injected, subcutaneously, in the right lateral flank, with 10 6 pLVX-TP-or pLVX-RMEL3-transduced cells. Mice were maintained with diet ad libitum and drinking water was supplemented with 1 mg/ml of doxycycline and changed every 2 days. Animals were monitored daily.
Tumor size was measured on days 8, 11, 14, 17, 21, and 24 after injections, and following this period the animals were euthanized. Tumor volumes were calculated using the formula V=LxW 2 x0.5, where W and L are, respectively, tumor width and length. All animal protocols and experiments were performed in accordance with the National Board for 
| Somatic mutation analyses
Analysis of somatic mutation in the RMEL3 locus was performed using two data sources: (1) The Cancer Genome Atlas (TCGA) data portal and (2) The International Cancer Genome Consortium (ICGC) data portal. We analyzed the RMEL3 locus for the presence of mutation in 450 melanomas of the TCGA dataset and 129 of the ICGC.
| Statistical analyses
All statistical analyses were performed using GraphPad Prism 5. All numerical data were expressed as the mean ±standard deviation.
F I G U R E 1 High RMEL3 expression predominates in BRAFV600E followed by NRAS mutant melanoma cell lines, as well as in nodular/ superficial spreading in comparison with acral/mucosal melanomas. (A) RT-qPCR analysis of RMEL3 RNA levels in melanocytes and melanoma cell lines of indicated genotype regarding major cancer drivers (BRAF, NRAS, and NF1). (B) RT-qPCR analysis of RMEL3 expression in melanoma subtypes: acral/mucosal and nodular/superficial spreading cutaneous melanoma, for which patient specimens were obtained from the Barretos Cancer Hospital, São Paulo state, Brazil. In A and B, relative expression was calculated according to 2 -∆∆CT method using TBP (Tata-box binding protein) as endogenous control, and the mean levels of RMEL3 RNA in different foreskin human melanocyte primary cultures were used as reference in both A and B, totaling the use of four different melanocyte cultures derived from different donors. Error bars represent SEM of 3 independent experiments. ***p < 0.005. Asterisks indicate statistically significant differences between groups based on Fisher's exact test. (Table S1 ). In the ICGC dataset, we found at least one mutation in 129 out of 129 melanomas, totaling 595 mutations, of which 28 mutations mapped upstream and 18 mutations downstream of the gene and the remaining majority of them were in the intronic regions, including ACTBL2 with 50 mutations (Table S2) . Except for 16 insertions or deletions in ICGC and 4 in TCGA, all the others were base substitutions. A summary of the number of different types of mutations detected in the TCGA and ICGC databanks is presented in Table S3 . We understand that the reduced number of mutations observed in the TCGA dataset compared to ICGC can be explained due to methodological differences, since TCGA was based on whole exome sequencing (WES)
while ICGC on whole genome sequencing (WGS). This difference also explains the fact that we did not find mutations upstream nor Figure   S1 ). Nevertheless, none of the mutations upstream nor downstream the gene were recurrent and only three of the intronic mutations occurred twice; thus, they do not appear to characterize a hotspot. Then, we correlated the RMEL3 mutations (excluding the ACTBL2 mutations) found in TCGA samples with the RMEL3 expression levels from RNAseq data available in the TCGA, and as shown in Figure 1d , there was no statistically significant correlation between mutation and expression. Therefore, the occurrence of these mutations does not explain the differential expression observed in Figure 1a ,b. Finally, using the TCGA dataset, we found that RMEL3 mutations are associated with poor patient survival rates ( Figure 1e ) (p < 0.05).
| Acute and prolonged MAPK inhibition decreases RMEL3 RNA levels in melanoma cells
We used specific drugs against oncogenic BRAF (vemurafenib/ Analysis of total ERK and phosphorylated ERK (Figure 2e ) demonstrates that both drug treatments effectively decreased pERK levels in the BRAFV600E mutant cells, whereas in WM1366, treatment with BRAF inhibitor increased pERK levels in the acute treatment, consistent with previously described paradoxical activation of ERK.
Next, we showed that treatment of UACC62 cells with the MEK inhibitor PD98059 (25 μM for 48 hr) reduced RMEL3 RNA levels by 77%, a condition in which pERK levels were also efficiently decreased ( Figure 2f ). As expected, treatments for 48 hr led to growth arrest, but did not cause a significant alteration in cell death rates ( Figure S2 ).
| RMEL3 expression in the NIH3T3
immortalized murine fibroblasts protects against serum withdrawal-induced growth arrest/ apoptosis and promotes clonogenic ability . After the indicated time points, cells were stained with crystal violet and cell density was quantified according to the absorbance in an ELISA microplate reader. ***p < 0.0005 (D) Apoptosis rate. Flow cytometry-based detection of annexin-V-and propidium iodide (PI)-stained cells. Dot plot from one assay representative of three replicates, and below, a summary graphics of three independent replicates. Cells were cultured in FBS-free medium for 48 h, and afterward, culture medium was supplemented with 0.5% FBS and cells were cultured for additional 48 h, when they were assayed. *p < 0.05; **p < 0.005. (E) Clonogenic ability. Cells were seeded in 60-mm-diameter plates and allowed to grow for 9 days, when they were fixed with paraformaldehyde and stained with crystal violet to reveal the colonies. *p < 0.05; **p < 0.005. Error bars represent SEM of 3 independent experiments for B-E. Asterisks indicate statistically significant differences between groups based on unpaired parametric Student's t test cultured in serum-free medium for 48 hr, and then, the medium was supplemented with 0.5% FBS, for a further 48-hr period, after which the cells were assayed for apoptosis (Figure 3d ). By the end of this regimen, the majority (~97%) of control cells were in early or late stages of apoptotic cell death as opposed to ~65% of RMEL3-overexpressing cells (Figure 3d ). Also, RMEL3-overexpressing NIH3T3 cells gained enhanced capacity of clonogenic growth as compared to control (Figure 3e ), increasing both colony number and colony size. 
|
| D ISCUSS I ON
Previous work from our laboratory has shown that RMEL3 lncRNA is highly enriched in melanoma, particularly in tumors harboring the oncogenic BRAFV600E (Goedert et al., 2016; Sousa et al., 2010) .
These studies have provided first evidence of the functional relevance of this lncRNA in melanoma owning to demonstration of its restricted expression pattern and the fact that its knockdown causes cell cycle arrest and dramatic decay of melanoma cell replicative survival, especially in BRAFV600E mutant cells, while treatment with the same siRNA preserves viability of cells that do not express detectable amounts of RMEL3. These effects were consistent with many alterations, in the RMEL3-silenced cells, of central regulators of the cell cycle and apoptosis, as well as signaling transduction components of the MAPK and PI3K pathways (Goedert et al., 2016) .
Here, we add evidence that high RMEL3 expression is more often associated with extensive superficial/nodular cutaneous melanoma than mucosal and acral melanoma. Recently, acral and mucosal melanomas were shown not to display the UV signature mutational burden observed in cutaneous melanoma ). This and a wealth of other evidence associating high content of UV signature mutations with cutaneous melanoma raised the possibility that Interestingly, however, RMEL3 mutation does correlate with poor patient survival raising the possibility that it could play a function as driver of tumorigenesis. Since we did not have access to expression data and survival information from ICGC, future studies should be pursued to answer whether mutations in the promoter region or additional mutations along the length of RMEL3 gene could influence its expression/function. We assume that, since mutation recurrence in the gene is rare, it is more likely that the association between RMEL3 mutation and poor patient survival rather than indicating a role of RMEL3 mutation as causative factor of tumorigenesis could just reflect an overall tumor mutational burden. After injections, mice were maintained with diet ad libitum and drinking water was supplemented with 1 mg/ml doxycycline and changed every 2 days. *p < 0.05. This experiment was done once. Asterisks indicate statistically significant differences between groups based on unpaired parametric Student's t test
The lack of a mutation hotspot and of a correlation between mutation and expression led us to conclude that activation of the RMEL3 gene in non-acral cutaneous melanoma is more likely to result from the MAPK/ERK activation that underlies the pathogenesis of this disease. This is consistent with previous evidence that nearly 90% of cutaneous melanomas in contrast to 56% of acral and mucosal melanomas carry mutation in one of the three genes, BRAF, NRAS, or NF1 . Also, because RMEL3 expression in BRAF mutant melanoma cell lines clearly reverses to the levels observed in melanocytes upon treatments with BRAF or MEK inhibitors, we favor the hypothesis that an active status of the MAPK/ ERK pathway is required for RMEL3 activation in the context of melanomagenesis. Moreover, the RMEL3 upregulation observed upon vemurafenib-induced paradoxical activation of ERK, in NRASQ61R mutant WM1366 cells, reinforces the notion that RMEL3 responds to ERK pathway activation and might be involved in the development of sporadic tumors or in the relapse of BRAFi-resistant melanoma (Nazarian et al., 2010) . There is precedent of lncRNAs with therapeutic potential in melanoma (Joung et al., 2017; Leucci, Vemdramin, et al., 2016) .
The activation of RMEL3 expression observed here in response to the status of the BRAF-MEK-ERK pathway activity raises the question of how to explain the highly restricted expression observed for RMEL3 in contrast to the well-known ubiquitous and canonical roles of the MAPK pathway. Our data suggest a dependence of the degree of activation of the ERK pathway and RMEL3 expression. We observed that acute exposure to a low concentration of vemurafenib decreased RMEL3 levels by about 50%, while more intense/prolonged inhibition was sufficient to bring RMEL3 levels in BRAFV600E cells to as low as the ones detected in melanocytes. Although it is beyond the scope of this work to clarify the mechanisms of RMEL3 transcriptional regulation, we discuss some evidence from ENCODE (Dunham et al., 2012) REST, whose stability is promoted by ERK inhibition (Nesti, Corson, McCleskey, Oyer, & Mandel, 2014) . ERK pathway was shown to cooperate for activation of Wnt/β-catenin signaling pathway in colon cancer, leading to activation of TCF7L2-repressed genes (Lemieux, Cagnol, Beaudry, Carrier, & Rivard, 2015) . Therefore, one of the above mechanisms could mediate the transcriptional regulation of RMEL3 downstream of ERK in melanoma. Notably, among the TFs occupying the RMEL3 locus, some are canonical factors for initiation of the serum response or involved in the immediate early response.
Prompted by the evidence discussed above and having previously shown that RMEL3 is required for survival of BRAF mutant melanoma cells (Goedert et al., 2016) , the major focus of this work was on defining the effects provoked by ectopic expression of RMEL3 in different cell lines and under a variety of culture conditions, especially serum starvation. We reasoned that if RMEL3 plays a role in, or downstream of mitogen/survival factor-stimulated signaling circuitries, under physiological conditions, its overexpression should bypass the necessity of mitogen stimulation for cell proliferation and survival. To test this hypothesis, we overexpressed RMEL3
in the immortalized, non-transformed, and widely known NIH3T3 murine fibroblasts (Meloche & Pouysségur, 2007; Wang et al., 2017) .
We were surprised to find that, indeed, overexpression of RMEL3
bypassed the requirement of a mitogen/survival factor stimulation to support cell proliferation and survival. These experiments also revealed that human RMEL3 lncRNA is functional in a murine cell line, and therefore, it must have conserved partners in this organism, despite low sequence conservation. Future studies will be necessary to define the underlying mechanisms of the protective role of RMEL3 against cell death caused by serum starvation.
The results discussed above led us to hypothesize that overexpression of RMEL3 would potentially enhance malignant properties of either a BRAF wild-type or a BRAF mutant melanoma cell line expressing low RMEL3 levels. Indeed, ectopic expression of RMEL3 using two different lentiviral vector systems enhanced cell proliferation in both cell lines, either cultured in complete media or under serum starvation. Most strikingly, expression mediated by a Dox-inducible vector system caused a strong increase in clonogenic ability and also promoted tumor growth in nude mice. These data are fully consistent with the phenotype shown previously for RMEL3 knockdown (Goedert et al., 2016) .
In conclusion, the protective effect of RMEL3 against serum withdrawal-induced cell cycle arrest and apoptosis together with other pharmacological and functional data shown here allow us to propose that RMEL3 gene is responsive to the ERK pathway and the RMEL3 lncRNA might play a key role as an activator/effector in the mitogen/survival factor response pathways. These capabilities and the highly restricted expression pattern of RMEL3 are desirable characteristics of targets for cancer drugs. by CNPq (465687/2014-8) .
CO N FLI C T O F I NTE R E S T
The author declares that there is no conflict of interest.
O RCI D
David E. Fisher https://orcid.org/0000-0002-5506-0575
Enilza M. Espreafico https://orcid.org/0000-0002-7552-4234
